|
1
|
Okura Y, Namisaki T, Moriya K, Kitade M,
Takeda K, Kaji K, Noguchi R, Nishimura N, Seki K, Kawaratani H, et
al: Combined treatment with dipeptidyl peptidase-4 inhibitor
(sitagliptin) and angiotensin-II type 1 receptor blocker (losartan)
suppresses progression in a non-diabetic rat model of
steatohepatitis. Hepatol Res. 47:1317–1328. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Saleh HA and Abu-Rashed AH: Liver biopsy
remains the gold standard for evaluation of chronic hepatitis and
fibrosis. J Gastrointestin Liver Dis. 16:425–426. 2007.PubMed/NCBI
|
|
3
|
Fujinaga Y, Namisaki T, Moriya K, Kitade
M, Kawaratani H, Shimozato N, Kaji K, Takaya H, Sawada Y, Seki K,
et al: Identification of clinical risk factors for histological
progression of primary biliary cholangitis. Hepatol Res.
49:1015–1025. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Venkatesh SK, Yin M, Takahashi N, Glockner
JF, Talwalkar JA and Ehman RL: Non-invasive detection of liver
fibrosis: MR imaging features vs. MR elastography. Abdom Imaging.
40:766–775. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Mattos AZ and Mattos AA: Transient
elastography vs. aspartate aminotransferase to platelet ratio index
in hepatitis C: A meta-analysis. Ann Hepatol. 16:349–357.
2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Yasui Y, Abe T, Kurosaki M, Matsunaga K,
Higuchi M, Tamaki N, Watakabe K, Okada M, Wang W, Shimizu T, et al:
Non-invasive liver fibrosis assessment correlates with collagen and
elastic fiber quantity in patients with hepatitis C virus
infection. Hepatol Res. 49:33–41. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Regev A, Berho M, Jeffers LJ, Milikowski
C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR and Schiff ER:
Sampling error and intraobserver variation in liver biopsy in
patients with chronic HCV infection. Am J Gastroenterol.
97:2614–2618. 2002.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Baranova A, Lal P, Birerdinc A and
Younossi ZM: Non-invasive markers for hepatic fibrosis. BMC
Gastroenterol. 11(91)2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Parikh P, Ryan JD and Tsochatzis EA:
Fibrosis assessment in patients with chronic hepatitis B virus
(HBV) infection. Ann Transl Med. 5(40)2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Terrault NA, Lok ASF, McMahon BJ, Chang
KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH and Wong JB: Update
on prevention, diagnosis, and treatment of chronic hepatitis B:
AASLD 2018 hepatitis B guidance. Hepatology. 67:1560–1599.
2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Drafting Committee for Hepatitis
Management Guidelines and the Japan Society of Hepatology. JSH
Guidelines for the management of hepatitis B virus infection.
Hepatol Res. 44 (Suppl 1):S1–S58. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kim BK, Kim DY, Park JY, Ahn SH, Chon CY,
Kim JK, Paik YH, Lee KS, Park YN and Han KH: Validation of FIB-4
and comparison with other simple noninvasive indices for predicting
liver fibrosis and cirrhosis in hepatitis B virus-infected
patients. Liver Int. 30:546–553. 2010.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Nishikawa H, Takata R, Enomoto H, Yoh K,
Kishino K, Shimono Y, Iwata Y, Hasegawa K, Nakano C, Nishimura T,
et al: Proposal of a predictive model for advanced fibrosis
containing Wisteria floribunda agglutinin-positive Mac-2-binding
protein in chronic hepatitis C. Hepatol Res. 47:E74–E84.
2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hansen JF, Juul Nielsen M, Nyström K,
Leeming DJ, Lagging M, Norkrans G, Brehm Christensen P and Karsdal
M: PRO-C3: A new and more precise collagen marker for liver
fibrosis in patients with chronic hepatitis C. Scand J
Gastroenterol. 53:83–87. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Luo Y, Oseini A, Gagnon R, Charles ED,
Sidik K, Vincent R, Collen R, Idowu M, Contos MJ, Mirshahi F, et
al: An Evaluation of the collagen fragments related to fibrogenesis
and fibrolysis in nonalcoholic steatohepatitis. Sci Rep.
8(12414)2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Yoshiji H, Noguchi R and Fukui H: Combined
effect of an ACE inhibitor, perindopril, and interferon on liver
fibrosis markers in patients with chronic hepatitis C. J
Gastroenterol. 40:215–216. 2005.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Casals G, Fernández-Varo G, Melgar-Lesmes
P, Marfà S, Reichenbach V, Morales-Ruiz M and Jiménez W: Factors
involved in extracellular matrix turnover in human derived
cardiomyocytes. Cell Physiol Biochem. 32:1125–1136. 2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Saw S, Zhao H, Tan P, Saw B and Sethi S:
Evaluation of the automated ADVIA centaur® XP syphilis
assay for serological testing. Diagn Microbiol Infect Dis. 88:7–11.
2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Hogemann B, Voss B, Pott G, Rauterberg J
and Gerlach U: 7 S collagen: A method for the measurement of serum
concentrations in man. Clin Chim Acta. 144:1–10. 1984.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Jekarl DW, Choi H, Lee S, Kwon JH, Lee SW,
Yu H, Kim M, Kim Y, Sung PS and Yoon SK: Diagnosis of liver
fibrosis with wisteria floribunda agglutinin-positive Mac-2 binding
protein (WFA-M2BP) among chronic hepatitis B patients. Ann Lab Med.
38:348–354. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Nielsen MJ, Nedergaard AF, Sun S, Veidal
SS, Larsen L, Zheng Q, Suetta C, Henriksen K, Christiansen C,
Karsdal MA and Leeming DJ: The neo-epitope specific PRO-C3 ELISA
measures true formation of type III collagen associated with liver
and muscle parameters. Am J Transl Res. 5:303–315. 2013.PubMed/NCBI
|
|
22
|
Noguchi R, Kaji K, Namisaki T, Moriya K,
Kitade M, Takeda K, Kawaratani H, Okura Y, Aihara Y, Furukawa M, et
al: Serum angiotensin-converting enzyme level for evaluating
significant fibrosis in chronic hepatitis B. World J Gastroenterol.
23:6705–6714. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Treatment with ursodeoxycholic acid in
clinical hepatology. Proceedings of a workshop. Goteborg, Sweden,
3-4 February 1994. Scand J Gastroenterol Suppl. 204:1–72.
1994.PubMed/NCBI
|
|
24
|
Intraobserver and interobserver variations
in liver biopsy interpretation in patients with chronic hepatitis
C. The French METAVIR Cooperative Study Group. Hepatology 20:
15-20, 1994.
|
|
25
|
Rossi E, Adams LA, Bulsara M and Jeffrey
GP: Assessing liver fibrosis with serum marker models. Clin Biochem
Rev. 28:3–10. 2007.PubMed/NCBI
|
|
26
|
Yamada N and Mizuta K: Advanced assessment
of serum Mac-2 binding protein glycosylation isomer in patients
with biliary atresia. J Gastroenterol. 54:204–205. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Shirabe K, Bekki Y, Gantumur D, Araki K,
Ishii N, Kuno A, Narimatsu H and Mizokami M: Mac-2 binding protein
glycan isomer (M2BPGi) is a new serum biomarker for assessing liver
fibrosis: More than a biomarker of liver fibrosis. J Gastroenterol.
53:819–826. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Bekki Y, Yoshizumi T, Shimoda S, Itoh S,
Harimoto N, Ikegami T, Kuno A, Narimatsu H, Shirabe K and Maehara
Y: Hepatic stellate cells secreting WFA+ -M2BP: Its role
in biological interactions with Kupffer cells. J Gastroenterol
Hepatol. 32:1387–1393. 2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Matsuura K, Aizawa N, Enomoto H,
Nishiguchi S, Toyoda H, Kumada T, Iio E, Ito K, Ogawa S, Isogawa M,
et al: Circulating let-7 levels in serum correlate with the
severity of hepatic fibrosis in chronic hepatitis C. Open Forum
Infect Dis. 5(ofy268)2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Ishii A, Nishikawa H, Enomoto H, Iwata Y,
Kishino K, Shimono Y, Hasegawa K, Nakano C, Takata R, Nishimura T,
et al: Clinical implications of serum Wisteria floribunda
agglutinin-positive Mac-2-binding protein in treatment-naive
chronic hepatitis B. Hepatol Res. 47:204–215. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Nishikawa H, Enomoto H, Iwata Y, Kishino
K, Shimono Y, Hasegawa K, Nakano C, Takata R, Nishimura T, Yoh K,
et al: Serum Wisteria floribunda agglutinin-positive Mac-2-binding
protein for patients with chronic hepatitis B and C: A comparative
study. J Viral Hepat. 23:977–984. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Miyaki E, Imamura M, Hiraga N, Murakami E,
Kawaoka T, Tsuge M, et al: Daclatasvir and asunaprevir treatment
improves liver function parameters and reduces liver fibrosis
markers in chronic hepatitis C patients. Hepatol Res.
2016;46(8):758-64.
|
|
33
|
Liu J, Hu HH, Lee MH, Korenaga M, Jen CL,
Batrla-Utermann R, et al: Serum Levels of M2BPGi as Short-Term
Predictors of Hepatocellular Carcinoma in Untreated Chronic
Hepatitis B Patients. Sci Rep. 2017;7(1):14352.
|
|
34
|
Nishimura T, Iijima H, Nishikawa H, Kondo
R, Yano H, Kage M, Aoki T, Nakano C, Yuri Y, Ishii N, et al: Liver
fibrosis markers as assessed by ultrasound elastography and serum
samples: A large comparative study in hepatitis virus B and C liver
diseases. Hepatol Res. 49:721–730. 2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Yasui Y, Kurosaki M, Komiyama Y, Takada H,
Tamaki N, Watakabe K, Okada M, Wang W, Shimizu T, Kubota Y, et al:
Wisteria floribunda agglutinin-positive Mac-2 binding protein
predicts early occurrence of hepatocellular carcinoma after
sustained virologic response by direct-acting antivirals for
hepatitis C virus. Hepatol Res. 48:1131–1139. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Nakamura M, Kanda T, Jiang X, Haga Y,
Takahashi K, Wu S, Yasui S, Nakamoto S and Yokosuka O: Serum
microRNA-122 and Wisteria floribunda agglutinin-positive Mac-2
binding protein are useful tools for liquid biopsy of the patients
with hepatitis B virus and advanced liver fibrosis. PLoS One.
12(e0177302)2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Mak LY, Wong DK, Cheung KS, Seto WK, Lai
CL and Yuen MF: Role of serum M2BPGi levels on diagnosing
significant liver fibrosis and cirrhosis in treated patients with
chronic hepatitis B virus infection. Clin Transl Gastroenterol.
9(163)2018.PubMed/NCBI View Article : Google Scholar
|
